title: Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis.
abstract: The interleukin-33 (IL-33)/ST2 pathway has emerged as an intercellular signaling system that participates in antigen-allergen response, autoimmunity and fibrosis. It has been suggested that IL-33/ST2 signaling has been involved in the pathogenesis of rheumatoid arthritis (RA), because IL-33 and its receptor have been specifically mapped to RA synovium. The aim of this study was to determine the levels of IL-33 and sST2 in sera and synovial fluids in patients with RA. The serum level of IL-33 was significantly higher in patients with RA (294.9 ± 464.0 pg/mL) than in healthy controls (96.0 ± 236.9 pg/mL, P = 0.002). The synovial fluid level of IL-33 was significantly higher in RA patients than in osteoarthritis patients. The level of serum sST2 was higher in RA patients than in healthy controls (P = 0.042). A significant relationship was found between the levels of IL-33 and IL-1β (r = 0.311, P = 0.005), and IL-33 and IL-6 (r = 0.264, P = 0.017) in 81 RA patients. The levels of IL-33, sST2 and C-reactive protein decreased after conventional disease-modifying antirheumatic drugs treatment in 10 patients with treatment-naïve RA. Conclusively, IL-33 is involved in the pathogenesis of RA and may reflect the degree of inflammation in patients with RA.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Yeon-Sik
authors.initials: YS
authors.lastname: Hong
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Moon
authors.forename: Young-Bin
authors.initials: YB
authors.lastname: Joo
authors.forename: Chan-Hong
authors.initials: CH
authors.lastname: Jeon
authors.forename: Mi-La
authors.initials: ML
authors.lastname: Cho
authors.forename: Ji Hyeon
authors.initials: JH
authors.lastname: Ju
authors.forename: Hye-Jwa
authors.initials: HJ
authors.lastname: Oh
authors.forename: Yu-Jung
authors.initials: YJ
authors.lastname: Heo
authors.forename: Sung-Hwan
authors.initials: SH
authors.lastname: Park
authors.forename: Ho-Youn
authors.initials: HY
authors.lastname: Kim
authors.forename: Jun-Ki
authors.initials: JK
authors.lastname: Min
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006801:Humans; D000072179:Interleukin-1 Receptor-Like 1 Protein; D053583:Interleukin-1beta / Q000032:analysis / Q000097:blood; D000067596:Interleukin-33; D015850:Interleukin-6 / Q000032:analysis / Q000097:blood; D007378:Interleukins / Q000032:analysis* / Q000097:blood; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000097:blood / Q000473:pathology; D011956:Receptors, Cell Surface / Q000032:analysis* / Q000097:blood; D013582:Synovial Fluid / Q000378:metabolism
chemical_list: D018501:Antirheumatic Agents; C079241:IL1RL1 protein, human; C506536:IL33 protein, human; D000072179:Interleukin-1 Receptor-Like 1 Protein; D053583:Interleukin-1beta; D000067596:Interleukin-33; D015850:Interleukin-6; D007378:Interleukins; D011956:Receptors, Cell Surface; D002097:C-Reactive Protein